Here's a startling fact: Even after successfully clearing hepatitis C (HCV) with powerful medications called direct-acting antivirals (DAAs), individuals living with HIV still face a lingering threat – hepatocellular carcinoma (HCC), a type of liver cancer. But here's where it gets hopeful: a recent study published in Clinical Infectious Diseases (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf635/8327002?login=false) reveals that the risk of developing HCC steadily declines each year following DAA treatment.
Researchers analyzed data from the multinational HepCAUSAL collaboration, tracking individuals with HIV-HCV coinfection for six years. They found that while the risk doesn't disappear entirely, the likelihood of HCC diminishes over time, assuming consistent DAA therapy. This suggests that the first few years after DAA treatment are critical for HCC surveillance in this population.
This finding is a double-edged sword. On one hand, it highlights the enduring impact of HCV on the liver, even after the virus is seemingly gone. On the other hand, it offers a glimmer of hope, indicating that DAAs may not only cure HCV but also reduce the long-term risk of liver cancer in people with HIV.
And this is the part most people miss: The study underscores the importance of continued monitoring for HCC, especially during the initial years post-DAA treatment. While DAAs are a game-changer for HCV, they aren't a magic bullet.
But here's the controversial question: Should HCC screening guidelines be adjusted to reflect this declining risk over time, potentially reducing the frequency of screenings after a certain point? Or is the risk still too significant to relax surveillance efforts?
The full story delves deeper into these findings and their implications (https://www.infectiousdiseaseadvisor.com/news/daa-therapy-linked-to-falling-hepatocellular-carcinoma-risk-in-hiv-hcv-coinfection/). Keep in mind, accessing more than five articles per month on Infectious Disease Advisor requires free registration.
What’s your take? Do you think HCC screening protocols need reevaluation based on this research? Share your thoughts in the comments below!
